Clinical Trials Logo

Filter by:
NCT ID: NCT04987307 Recruiting - Ulcerative Colitis Clinical Trials

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Start date: January 31, 2022
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in the opinion of the investigator, they may benefit from continued treatment. During the long-term period, participants randomized to efavaleukin alfa will remain on the same efavaleukin alfa blinded dose; participants randomized to placebo who achieved clinical response at week 12 will remain on placebo; and placebo non-responders (ie, participants randomized to placebo who did not achieve clinical response at week 12) will receive efavaleukin alfa in a blinded manner during continued treatment. All participants will complete a safety follow-up visit 6 weeks after their last dose of investigational product.

NCT ID: NCT04987203 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Start date: September 9, 2021
Phase: Phase 3
Study type: Interventional

This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).

NCT ID: NCT04986891 Recruiting - CIPN Clinical Trials

Chemotherapy Induced Peripheral Neurotoxicity (CIPN): Why Should we Care

CIPN COST
Start date: July 31, 2021
Phase:
Study type: Observational

This is a pilot, observational, cross-sectional, study on socio-economic burden related to chemotherapy-induced peripheral neurotoxicity (CIPN). Investigators will collect CIPN healthcare related costs on a detailed clinical patient-level. As a sub-study, data obtained in this cross-sectional study, will be compared with administrative larger datasets on patients affected by cancer. The aim is to run a test for potential proxy variables which are available in larger administrative datasets, even if not directly measuring CIPN, to learn more about the impact of CIPN.

NCT ID: NCT04986332 Recruiting - Heart Failure Clinical Trials

Multidimensional Approach for COPD and High Complexity

MACH
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The MACH Study trial will examine the impact on high complexity COPD patients of a multidimensional approach (moderate-intensity physical activity program and clinic-therapeutic re-evaluation of the participants)

NCT ID: NCT04985968 Terminated - Ulcerative Colitis Clinical Trials

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

CONCLUDE
Start date: November 24, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC and to evaluate the efficacy of cobitolimod maintenance treatment compared to placebo in inducing or maintaining clinical remission at week 52, in participants with clinical response at week 6 after induction treatment with cobitolimod.

NCT ID: NCT04985240 Completed - Healthy Diet Clinical Trials

Intervention Study on Molibdenum Biofortification Vegetables ( Nutri-Mo-Food )

NutMoFood
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The aim of the project is to study of the influence of Lettuce crop enriched with Molibdenum on hematological parameter. Secondary outcome to find out Molibdenum presence in urine in order to evaluate vegetables, like little crop, as Molibdenum biocarrier.

NCT ID: NCT04984876 Terminated - Allergy, Peanut Clinical Trials

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Start date: December 7, 2021
Phase: Phase 3
Study type: Interventional

This is a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) subcutaneous injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy.

NCT ID: NCT04984785 Completed - Obesity Clinical Trials

Lipid Metabolism in Obese Subjects Undergoing Bariatric Surgery

Start date: February 1, 2019
Phase:
Study type: Observational

The aim of the study is to evaluate modifications in the metabolism of polyunsaturated fatty acids (PUFA) and biosynthesis of the lipid mediators N-acylethanolamines (NAE), both known to induce and be induced by the nuclear peroxisome proliferator-activated receptor (PPAR)-α, which may also explain the well-established improved lipid and energy metabolism after bariatric surgery. The study is focused on understanding the weight loss mechanisms in order to develop targeted dietary protocols.

NCT ID: NCT04984746 Completed - Healthy Diet Clinical Trials

Intervention Study on Iodine and Molybdenum Biofortification Vegetables ( Nutri-I-Mo )

Nutr-I-Mo
Start date: April 2, 2021
Phase: N/A
Study type: Interventional

The aim of the project is to study the influence of Lettuce crop enriched with Molybdenum and lettuce enriched with Iodine administrated at the same time on healthy population in order to assess influence on hematological parameter and Thyroid hormones. Secondary outcome will be to find out Molybdenum and Iodine presence in urine in order to evaluate vegetables as biocarrier and any additive effect when administrated all together.

NCT ID: NCT04983849 Completed - Periodontitis Clinical Trials

Evaluation of Metronidazole Hydrogel 25% in Stage II and III Periodontitis

Start date: July 7, 2021
Phase: Phase 4
Study type: Interventional

A randomized clinical trial will be performed single-blind to evaluate the effectiveness of sublingual metronidazole hydrogel 25 % in periodontitis.